Prostate Cancer - Results from #23820

GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster February 19, 2013

Understanding and implementing immunotherapy for prostate cancer, by Charles G. Drake, MD, PhD of Johns Hopkins Kimmel Cancer Center February 19, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED, by A. Oliver Sartor, MD, et al. - Poster February 19, 2013

Agents that target androgen synthesis in castration-resistant prostate cancer - Abstract February 19, 2013

Value of real-time elastography to guide the systematic prostate biopsy in men with normal digital rectal exam - Abstract February 19, 2013

Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: Mechanism and biomarkers - Abstract February 18, 2013

Current role of salvage robotic-assisted laparoscopic prostatectomy - Abstract February 18, 2013

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort - Abstract February 18, 2013

The consistency of Gleason scores may effect the operation outcomes for laparoscopic radical prostatectomy: A single surgeon and a single pathologist data - Abstract February 18, 2013

Is it presently reasonable to propose prostate cancer screening? Questions and answers - Abstract February 18, 2013

Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: Identification of risk categories according to number of positive nodes and Gleason score - Abstract February 18, 2013

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy - Abstract February 18, 2013

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer - Abstract February 18, 2013

GU Cancers Symposium 2013 - Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor, by Howard I. Scher, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Updated interim analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in patients with metastatic castration-resistant prostate cancer without prior chemotherapy, by D. E. Rathkopf, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up, Andrew Loblaw, MD, FRCPC, MSc - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study, by Abdenour Nabid, et al. - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Novel strategies for targeting the androgen-receptor axis: PARP1 as a mediator of androgen receptor-dependent transcriptional control, by Karen E. Knudsen, PhD - Session Highlights February 15, 2013

The changing landscape in the treatment of metastatic castration-resistant prostate cancer - Abstract February 15, 2013

Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: Optimal b value at 3T - Abstract February 15, 2013

Page 1192 of 1436